XXII - Rodman & Renshaw Research Report - May 2011.
22nd Century Ltd, LLC (OTCBB: XXII; Twitter: $XXII) is a plant biotechnology company and the global leader in modifying the content of nicotinic alkaloids in plants, including the tobacco plant, through genetic engiineering and plant breeding.
XXII - Rodman & Renshaw Research Report - May 2011.
22nd Century Ltd, LLC (OTCBB: XXII; Twitter: $XXII) is a plant biotechnology company and the global leader in modifying the content of nicotinic alkaloids in plants, including the tobacco plant, through genetic engiineering and plant breeding.
CytoSorbents Corporation (OTCBB: CTSO) is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In March 2011, CytoSorb™, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in cases where cytokines are elevated.
Unilife Corp. (NASDAQ: UNIS; Stock Twits: $UNIS) is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication.
Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. Our lead products are: Iferanserin (VEN 309) for the topical treatment of hemorrhoids, for which the first Phase III clinical trial began in August 2011 and is ongoing, and topical Diltiazem for the treatment of anal fissures for which the first Phase III trial was initiated November 2010, and is ongoing. Our product candidate portfolio also includes topical phenylephrine intended to treat fecal incontinence (VEN 308). VEN-307 and VEN-308 are two molecules that were previously approved and marketed for other indications and that have been formulated into our in-licensed proprietary topical treatments for these new gastrointestinal indications, and VEN 309 is a New Chemical Entity (NCE).
Davenport Chiropractor, Dr. Clay, has prepared a presentation on proper shoveling posture and form. This presentation includes core stability exercises to help prevent injury during snow removal.
AVReporter Schneider Electric M221 plc impulse counterAvreporter KONsys
This document describes the components and procedures required to specify and deliver a simple consumption monitoring and reporting solution, using a Schneider Electric M221 PLC and AVReporter v3.0 software.
CytoSorbents Corporation (OTCBB: CTSO) is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In March 2011, CytoSorb™, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in cases where cytokines are elevated.
Unilife Corp. (NASDAQ: UNIS; Stock Twits: $UNIS) is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication.
Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. Our lead products are: Iferanserin (VEN 309) for the topical treatment of hemorrhoids, for which the first Phase III clinical trial began in August 2011 and is ongoing, and topical Diltiazem for the treatment of anal fissures for which the first Phase III trial was initiated November 2010, and is ongoing. Our product candidate portfolio also includes topical phenylephrine intended to treat fecal incontinence (VEN 308). VEN-307 and VEN-308 are two molecules that were previously approved and marketed for other indications and that have been formulated into our in-licensed proprietary topical treatments for these new gastrointestinal indications, and VEN 309 is a New Chemical Entity (NCE).
Davenport Chiropractor, Dr. Clay, has prepared a presentation on proper shoveling posture and form. This presentation includes core stability exercises to help prevent injury during snow removal.
AVReporter Schneider Electric M221 plc impulse counterAvreporter KONsys
This document describes the components and procedures required to specify and deliver a simple consumption monitoring and reporting solution, using a Schneider Electric M221 PLC and AVReporter v3.0 software.